To-BBB Scores €4M to Advance Doxorubicin-Based Drug into the Clinic
2B3-101 was developed on firm’s G-Technology, which enhances delivery to the brain.!--h2>
To-BBB obtained €4 million from its Series B investment round. The money is expected to allow the firm to move its lead product, a brain cancer candidate, into the clinic and to develop other potential CNS therapies that utilize the company’s G-Technology® for brain drug delivery. This Series B round supplemented by additional governmental funding programs will support the company for two years, to-BBB predicts.
To-BBB’s lead program is applying the G-Technology for the delivery of doxorubicin for the treatment of multiple brain cancer types. The product, called 2B3-101, is initially being studied in patients with brain metastases of breast cancer. The study is expected to start in the second quarter for this year and is planned to enroll 30 patients.
The G-Technology combines pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand. In the last year to-BBB says that it has signed 10 collaborations with pharma companies to explore use of this platform for development of CNS therapies. To-BBB says that it is working on treatments for neurodegenerative diseases and lysosomal storage diseases by combining existing drugs with the G-Technology.